The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models.
Marc MasanasNuria MasiáLeticia Suárez-CabreraMireia OlivanAroa SorianoBlanca MajemLaura Devis-JaureguiRebeca Burgos-PanaderoCarlos JiménezPau Rodriguez-SodupeAriadna BoloixIgnasi ToledanoGabriela GuillénAlexandra NavarroDavid Llobet-NavasAlberto VillanuevaJosep Sánchez de ToledoJosep RomaRosa NogueraLucas MorenoRolf KraussSoledad GallegoAnna SantamariaMiguel F SeguraPublished in: Clinical and translational medicine (2022)